- Home
- NUVL vs CIGI Comparison
NUVL vs CIGI Comparison
Compare NUVL & CIGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CIGI
- Stock Information
- Founded
- NUVL 2017
- CIGI 1972
- Country
- NUVL United States
- CIGI Canada
- Employees
- NUVL N/A
- CIGI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CIGI
- Sector
- NUVL Health Care
- CIGI
- Exchange
- NUVL Nasdaq
- CIGI Nasdaq
- Market Cap
- NUVL 5.8B
- CIGI 6.8B
- IPO Year
- NUVL 2021
- CIGI N/A
- Fundamental
- Price
- NUVL $80.89
- CIGI $165.86
- Analyst Decision
- NUVL Strong Buy
- CIGI Buy
- Analyst Count
- NUVL 11
- CIGI 7
- Target Price
- NUVL $120.91
- CIGI $171.83
- AVG Volume (30 Days)
- NUVL 429.4K
- CIGI 139.0K
- Earning Date
- NUVL 08-07-2025
- CIGI 11-04-2025
- Dividend Yield
- NUVL N/A
- CIGI 0.18%
- EPS Growth
- NUVL N/A
- CIGI N/A
- EPS
- NUVL N/A
- CIGI 2.21
- Revenue
- NUVL N/A
- CIGI $5,169,495,000.00
- Revenue This Year
- NUVL N/A
- CIGI $16.18
- Revenue Next Year
- NUVL N/A
- CIGI $7.46
- P/E Ratio
- NUVL N/A
- CIGI $73.03
- Revenue Growth
- NUVL N/A
- CIGI 16.63
- 52 Week Low
- NUVL $55.54
- CIGI $100.86
- 52 Week High
- NUVL $113.51
- CIGI $170.65
- Technical
- Relative Strength Index (RSI)
- NUVL 61.76
- CIGI 64.88
- Support Level
- NUVL $73.28
- CIGI $159.34
- Resistance Level
- NUVL $81.10
- CIGI $170.65
- Average True Range (ATR)
- NUVL 2.51
- CIGI 2.98
- MACD
- NUVL 0.77
- CIGI -1.02
- Stochastic Oscillator
- NUVL 83.27
- CIGI 57.65
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CIGI Colliers International Group Inc. Subordinate Voting Shares
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are; Real Estate Services, Engineering, Investment Management, and Corporate. Maximum revenue for the company is generated from its Real Estate Services segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, property sales brokerage, and lease brokerage services, among others. Geographically, the company generates maximum revenue from the United States and the rest from Canada, Australia, the United Kingdom, Poland, China, India, and other regions.